In the rapidly evolving world of biotechnology, marking a 25-year anniversary not only reflects longevity but also a significant contribution to science and human health. Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Under the guidance of Co-Founder and current CEO Jan van de Winkel, Genmab has remained committed to its core mission: harnessing the power of human antibodies to improve the lives of patients worldwide. In this exclusive ..read more

In this episode, Ayesha spoke with William Schaffner, MD, Professor of Preventive Medicine Health Policy and Professor in the Division of Infectious Diseases at Vanderbilt University; and Kelly Moore, MD, MPH, President and CEO at Immunize.org and Associate Professor of Health Policy at Vanderbilt University.                   Dr. Schaffner and Dr. Moore discussed the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation of a trivalent influenza vaccine strain selection, as opposed to a typical quadrivalent vacci ..read more

In this exclusive video interview, we had the opportunity to sit down with Wendy Erler, Vice President, Global Head of Patient Experience, Patient Advocacy and Patient and Caregiver Insights at AstraZeneca, for an in-depth discussion. This video interview delves into AstraZeneca’s patient-centric approach and how it influences its R&D strategy for rare diseases. From her perspective, Wendy also shares the most significant insights gained about rare diseases in recent years, and more. XTALKS CLINICAL EDGE: Issue 2 — Special Focus on Rare Disease Clinical Research Xtalks Clinical Edge is a ..read more

World Asthma Day 2024 is organized on an annual basis to raise awareness about asthma, a prevalent chronic respiratory disease affecting millions worldwide. Every year, the first Tuesday of May is celebrated as World Asthma Day. It was initiated in 1998 by the Global Initiative for Asthma (GINA), which collaborates with healthcare groups and asthma educators to improve awareness about asthma and related care around the globe. A specific theme focusing on an aspect of asthma care or management is highlighted each year; the theme for World Asthma Day 2024 is “Asthma Education Empowers.” World As ..read more

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. While it isn’t known whether 2024 might beat that record, it will surely be a busy year for the agency. Since January, the FDA has already signed off on more than a dozen novel drugs. Among these are Madrigal Pharmaceuticals’ resmetirom (branded Rezdiffra), which secured FDA approval in March for the treatment of nonalcoholic steatohepatitis (NASH) and sotatercept (commercial name Winrevair) for pulmonary hypertension (PAH). The agency is reviewing applications for several highly antici ..read more

Learn how to aggregate, integrate, standardize, manage and use clinical trial data from multiple sources. With seamless access to integrated data from different sources, you can provide your teams with a complete data management and quality experience. Understand how using AI to streamline workflows for multiple users to review real-time data can reduce timelines and risk and ensure safety. Key benefits: Increase speed to high-quality data, without increasing headcount Lower risk to the trial and help sites perform better Transform data for review/analysis in low/no-code experience Simplify d ..read more

In this episode, Ayesha spoke with Robert Barrow, CEO and Board Director at MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing innovative psychedelic-based product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. Robert Barrow Chief Executive Officer and Board Director MindMed Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug develop ..read more

Heart failure, affecting over 64 million people worldwide, remains a formidable challenge in the medical community despite advancements in pharmacotherapy over the past decade. The prognosis for heart failure patients is disheartening, with a mere half surviving beyond five years post-diagnosis. This stark reality highlights the urgent need for novel heart failure management options, particularly for advanced stages of the disease. The economic impact is also staggering, with heart failure leading as the top cardiac diagnosis among Medicare patients, reinforcing the demand for innovative care ..read more

April marks not only the blossoming of spring and the onslaught of my allergies but also a pivotal moment for raising awareness and advocating for equitable healthcare access. National Minority Health Month, observed annually throughout April, serves to emphasize the recognition of the unique health challenges faced by minority communities. This month-long observance is not just a symbolic gesture; it’s a critical opportunity to take a deeper dive to open up dialogue and cast our focus on disparities, promote health equity and catalyze meaningful change. In 1914, Booker T. Washington, an Ameri ..read more

John K. Celebi, MBA President and Chief Executive Officer Sensei Biotherapeutics In this episode, Ayesha spoke with John K. Celebi, MBA, President & Chief Executive Officer, Sensei Biotherapeutics, a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Sensei Biotherapeutics specializes in creating conditionally active antibodies engineered to operate specifically within the acidic tumor microenvironment, enhancing the immune system’s ability to combat cancer. John Celebi, MBA, has over 25 years of experience ..read more